Law360 (February 13, 2020, 4:20 PM EST) -- The U.S. Food and Drug Administration and the Federal Trade Commission issued warning letters to various CBD manufacturers in 2019 alleging a number of violations, including unsubstantiated advertising claims, and marketing and selling unapproved new drugs and unapproved dietary supplements. Since the warning letters were issued, CBD companies are being hit with an increasing number of class actions.
While a few lawsuits were filed against CBD companies prior to the regulators’ warning letters — from shareholder derivative suits to allegations of CBD products impermissibly containing THC, resulting in a failed drug test — the class actions filed after the October and...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!